Eye care therapies on the move: What’s in the pipeline
September 16th 2022Melissa Barnett, OD, from the University of California, Davis Eye Center, Sacramento and Davis, CA, described new strategies, technologies, and drug classes to treat chronic conditions that include myopia, Demodex infestation, meibomian gland dysfunction, glaucoma drug delivery, advancements in corneal and cataract surgeries, and presbyopia
VEW 2022: New dark adaptation modality and other pipeline updates from Heru
September 15th 2022Brandon Barber, chief marketing officer at Heru, shares about the company's new dark adaptation modality, which they announced during the 2022 Vision Expo West, as well as other advancements in the pipeline.
Azura Ophthalmics receives grant for leading CLD clinical candidate
September 10th 2022Azura has secured funding to support its 2-stage study evaluating the safety, tolerability, and efficacy of AZR-MD-001, its leading candidate, for patients with contact lens discomfort who show signs of meibomian gland dysfunction.